Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $45.25.
Several equities analysts have weighed in on the company. Wall Street Zen raised Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Stifel Nicolaus assumed coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. Jefferies Financial Group started coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price target on shares of Braveheart Bio in a research report on Tuesday, October 20th. Finally, The Goldman Sachs Group started coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price target for the company.
View Our Latest Report on Braveheart Bio
Braveheart Bio Trading Up 5.8%
NASDAQ BRVE opened at $20.39 on Friday. Braveheart Bio has a 1-year low of $16.70 and a 1-year high of $32.00. The company has a 50 day simple moving average of $21.23. The firm has a market capitalization of $1.83 billion and a P/E ratio of -6.75.
Braveheart Bio (NASDAQ:BRVE – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.40. Research analysts predict that Braveheart Bio will post -1.97 earnings per share for the current year.
Hedge Funds Weigh In On Braveheart Bio
Hedge funds have recently bought and sold shares of the company. a16z Capital Management L.L.C. acquired a new position in shares of Braveheart Bio in the 3rd quarter valued at approximately $206,695,000. RA Capital Management L.P. bought a new stake in shares of Braveheart Bio during the 3rd quarter worth approximately $11,413,000. Integral Health Asset Management LLC acquired a new stake in shares of Braveheart Bio during the 3rd quarter worth approximately $2,020,000. Goldman Sachs Group Inc. acquired a new stake in shares of Braveheart Bio during the 3rd quarter worth approximately $841,000. Finally, Ghisallo Capital Management LLC acquired a new stake in shares of Braveheart Bio during the 3rd quarter worth approximately $404,000.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
Featured Stories
- Five stocks we like better than Braveheart Bio
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
